Dr. Ahmed Hidradenitis suppurativa (HS) is a skin abnormality that is chronic in nature, and it affects the hair follicles and sweat glands.
In this condition, there is a development of painful nodules, abscesses, and scarring in areas where the skin rubs together, such as armpits, groin, and buttocks.
Because of such reasons, this can cause extreme discomfort and affect a person’s quality of life.
Not only this, HS can also affect the victim’s mental health. Similarly, physical pain and emotional distress linked to HS can cause episodes of isolation, depression, and anxiety.
Moreover, the apparent form of HS can make it difficult for people to maintain their self-esteem and confidence.
These problems can have a significant effect on a human’s overall well-being and ability to participate completely in social and professional activities.
Although the HS global prevalence is 0.00033– 4.1%, which means it is low, and its prevalence among European and U.S. populations is a little higher at 0.7– 1.2% [ref].
Previous studies have expressed that obesity and HS are linked together [ref]. Still, it has not been studied as much, which is why recent research has attempted to establish a clear link between the two conditions.
The review aimed to provide a systematic and comprehensive overview of the existing evidence, identify knowledge gaps, and inform future research and clinical practice.
Methodology:
The study used a thorough method to find and examine important studies. Researchers searched through several databases like PubMed, Scopus, and Web of Science, using key terms such as “hidradenitis suppurativa,” “obesity,” “pediatric,” and “children.”
They only looked at studies published from January 2010 to December 2020 to make sure they included the most recent research.
To make sure the studies were high-quality and relevant, some rules were used to decide which ones to include or exclude. Studies were included if they:
- Focused on children
- Looked at the link between obesity and HS
- Gave numbers on how common obesity is in HS patients
- Were published in peer-reviewed journals.
Studies were not included if they were case reports, review articles, or if they did not meet the criteria listed above.
Two separate reviewers collected the data using a set form and discussed any disagreements to reach an agreement. The quality of the studies was checked using the Newcastle-Ottawa Scale (NOS).
Key findings:
From their results they found a proper link between obesity and pediatric hidradenitis suppurativa (HS).
Kids with HS were at a higher risk of being obese or overweight compared to the general public. Similarly, the prevalence of obesity was much higher in HS patients (42.3%) than in the general population (18.7%).
Moreover, they also discovered that the severity of HS was correlated to the degree of obesity, so patients with higher BMI experienced more severe symptoms.
These findings suggest a strong link between obesity and HS in children, highlighting the importance of addressing both conditions for optimal management and improving the quality of life for affected individuals.
Prevention and management of obesity and pediatric hidradenitis suppurativa
Now that we know that obesity and HS are interlinked it is better to focus on its management and prevention.
Both conditions can impact and degrade a person’s quality of life so effective strategies are the best choice here.
Prevention Strategies
Healthy Lifestyle – Encouraging children to follow a healthy lifestyle, including regular physical activity, a balanced diet, and proper sleep, can help prevent both obesity and HS.
Weight Management – For kids who are overweight or obese, using weight management methods under the guidance of a healthcare professional can be beneficial. This might involve dietary changes, increased physical activity, and behavioral interventions.
Skin Care – Good skin hygiene can help prevent HS flares. This includes gentle cleansing of affected areas, avoiding tight-fitting clothing, and using mild, fragrance-free products.
Management of HS
HS is frequently managed with a combination of medical treatments, including:
- Corticosteroids and antibiotics may help reduce inflammation and control infections.
- Antibiotics, hormonal therapy, and immunosuppressants may be used in more severe cases.
- Adalimumab (Humira), and Ruxolitinib (Opzelura) are biological medications from the TNF-inhibitors class and JAK inhibitors respectively, approved by the FDA for the treatment of hidradenitis suppurativa (HS).
- Ruxolitinib (Opzelura) is available as a topical skin cream.
- In some cases, surgical procedures may be necessary to drain abscesses, remove sinus tracts, or reduce scarring.
Addressing both conditions simultaneously
A team approach with healthcare professionals like dermatologists, pediatricians, nutritionists, and psychologists can offer well-rounded care for kids dealing with both obesity and HS.
Proper treatment plans that target both conditions together can lead to better results and lessen the impact of the diseases.
Offering emotional support and counseling can also help children and their families handle the difficulties of obesity and HS more easily.
It is good to talk to a healthcare professional for personal advice on preventing and managing obesity and pediatric hidradenitis suppurativa.
People must act early and use a complete treatment plan to greatly improve the health and well-being of children affected by these conditions.
Conclusion
The study highlights the importance of recognizing obesity as a possible risk factor for developing Hidradenitis Suppurativa in children.
This new research helps healthcare professionals give better and more complete care to children dealing with this difficult condition.
By getting the link between obesity and HS, doctors can create treatment plans that help both problems, which can lead to better results and a higher quality of life for children.
Additionally, recognizing how obesity contributes to HS can help shape public health programs that encourage healthier living. These initiatives may help prevent both obesity and HS from developing in children.
